ClinicalTrials.gg
CompletedNCT06156280Updated Mar 25, 2025

A Clinical Study of TQH2929 in Healthy Adult Subjects

A Phase 1 interventional study of TQH2929 injection and Placebo injection in Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
146th of 182
40 · median 171
Started
2023
with 27 others
Phase 1
37 of 206
5 open now
Registered
121st of 206
by date
Lead sponsor
5 of 206
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 206 studies in Psoriasis with a site in China, this one is the 146th largest by enrollment of the 182 interventional ones that give a count, is one of 28 that started in 2023, is one of 37 in phase 1, and was the 121st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This project is divided into a single dose escalation and a multiple dose escalation phase Ia clinical study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929 injection in healthy adults.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged between 18 and 55 years old (inclusive), both male and female;
  • The male subject should weigh at least 50 kg, the female subject should weigh at least 45kg. And (BMI) within 19\~26 kg/m2.
  • Good health is defined as having no abnormalities identified by a detailed medical history, clinical signs, vital signs, full physical examination, 12-lead (ECG), Chest radiograph, abdominal ultrasound and clinical laboratory tests.
  • Subjects voluntarily joined the study, sign form before the study and fully understand the study content.
  • Have no pregnancy plan and voluntarily take effective measures from time of screening to at least 6 months after the last dose (subjects and their partners).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Past medical history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic abnormalities, or related chronic diseases, or acute diseases, and evaluated the investigator to be not suitable for the trial;
  • People who have abnormal and results in vital signs, physical examination, laboratory tests, 12-lead , Chest radiograph and abdominal ultrasound during screening period;
  • Subjects positive for any of Virus Surface Antigen (HBsAg), Virus Antibody (Anti-HCV), Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP) tests;
  • Subjects positive for tuberculoses spot (T-SPOT) result;
  • Clinically significant infection requiring antibiotic or antiviral therapy prior to screening and the entire study period;
  • Had undergone surgery within 4 weeks prior to screening period or expected to undergo surgery during the study period;
  • Participated in any clinical trial within 3 months prior to the screening period;
  • Received immunoglobulins or blood products within 30 days prior to randomization;
  • Blood donation or significant blood loss of more than 400 mL within 2 months prior to randomization;
  • People who have potential difficulty in blood collection, or have a history of needles or blood sickness;
  • Any clear history of drug or food allergies, particularly those with allergies to similar components to the drugs in this trial;
  • People who have received or are planning to receive inactivated or active vaccines during the 30 days prior to randomization and the entire study period (including the follow-up period);
  • Smoking more than 5 cigarettes per day or using equivalent amounts of nicotine or nicotine-containing products within 6 months prior to randomization, or those who cannot stop using any tobacco-based products during the trial;
  • People who had long-standing alcohol abuse or alcohol consumption of more than 14 units (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) of alcohol per week within 3 months prior to screening, or those who cannot refrain from alcohol during the trial, or those who tested positive for alcohol breath;
  • History of drug abuse or a positive result of urine drug test at screening;
  • Received any marketed or investigational biologics within 4 months or 5 half-lives (whichever is longer) prior to randomization;
  • Had taken any prescription drugs, over-the-counter drugs, or herbs within 4 weeks prior to randomization, with the exception of vitamin products;
  • Use of any systemic cytotoxicity or systemic within 6 months prior to randomization or during the study period, or any local cytotoxin or local immunosuppressive drug within 30 days or 5 half-life periods (whichever is longer) prior to randomization or during the study period;
  • Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TQH2929 Injection (1 mg/kg)

    TQH2929 Injection 1 mg/kg is administered as a single dose.

    Drug: TQH2929 injection

  • Experimental
    TQH2929 Injection (3 mg/kg)

    TQH2929 Injection 3 mg/kg is administered as a single dose.

    Drug: TQH2929 injection

  • Experimental
    TQH2929 Injection (10 mg/kg)

    TQH2929 Injection 10 mg/kg is administered as a single dose.

    Drug: TQH2929 injection

  • Experimental
    TQH2929 Injection (20 mg/kg)

    TQH2929 Injection 20 mg/kg is administered as a single dose.

    Drug: TQH2929 injection

  • Experimental
    TQH2929 Injection (30 mg/kg)

    TQH2929 Injection 30 mg/kg is administered as a single dose.

    Drug: TQH2929 injection

  • Placebo comparator
    Placebo Injection

    Placebo injection is administered as a single dose or multiple doses (once every two weeks).

    Drug: Placebo injection

Interventions

  • TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

  • DrugPlacebo injection

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Adverse events (AE) rate

    The occurrence of all adverse events (AE).

    Time frame: Single dose: Up to Day 113

  2. Serious adverse events (SAE) rate

    The occurrence of all adverse events (SAE).

    Time frame: Single dose: Up to Day 113

  3. Treatment-related adverse events (TRAE) rate

    The occurrence of all treatment-related adverse events (TRAE).

    Time frame: Single dose: Up to Day 113

  4. Incidence of clinical laboratory abnormalities

    Proportion of subjects with clinical laboratory abnormalities

    Time frame: Single administration dose (SAD) group: up to Day 113

Secondary outcomes

  1. Time to reach maximum observed serum concentration (Tmax), SAD

    Time to reach maximum (peak) serum concentration after administration in SAD group

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  2. Maximum serum concentration (Cmax), SAD

    The maximum observed serum concentration of study drug in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  3. Area under the concentration-time curve from zero to infinity (AUC 0-∞), SAD

    Area under the concentration-time curve of the TQH2929 Injection in serum over the time interval from 0 extrapolated to infinity in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  4. Area under the concentration-time curve from 0 to last observation (AUC 0-t), SAD

    Area under the concentration-time curve of the TQH2929 Injection in serum over the time interval from 0 extrapolated to the last quantifiable data time-point in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  5. Apparent volume of distribution (Vd/F), SAD

    Apparent volume of distribution of the TQH2929 Injection in serum in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  6. Apparent clearance (CL/F), SAD

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body, in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  7. Half-life (t1/2), SAD

    The time required for half of the drug to be eliminated from the serum in SAD group.

    Time frame: 1 hour pre-dose, 0, 0.5, 1, 2, 6, 12, 24, 48, 72, 168, 336, 504, 672, 840, 1008, 1344, 1680, 2016, 2353, 2688 hours postdose.

  8. Anti-drug antibodies (ADA)

    Proportion of subjects with a positive ADA reading at any time point during the study.

    Time frame: SAD group: 1 hour pre-dose, postdose on Day 15, Day 57, Day 85, Day 113.

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing 100871, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Aug 2024, 8 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 5, 2023
StartActual
Nov 21, 2023
Primary completionActual
Aug 2, 2024
CompletionActual
Mar 21, 2025
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06156280
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Nov 21, 2023
Primary completion
Aug 2, 2024
Completion
Mar 21, 2025
Last update
Mar 25, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2929

Start the discussion